Loading...
Top Strike Resources Corp.
VENI.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.01
CA$0.005(100.00%)

The company's financials show resilient growth, with revenue advancing from $0.00 in Q3 2023 to $1.16M in Q2 2024. Gross profit remained healthy with margins at 26% in Q2 2024 compared to N/A in Q3 2023. Operating income hit $0.00 last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$290458.00. Net income rose to -$545645.00, while earnings per share reached $0.00. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan